Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles

A group of clinically approved cancer therapeutic tyrosine kinase inhibitors was screened to test their effects on the expression of angiotensin-converting enzyme 2 (ACE2), the cell surface receptor for SARS-CoV-2. Here, we show that the receptor tyrosine kinase inhibitor imatinib (also known as STI...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, You-Zhe, Shen, Yi-Chun, Wu, Wan-Rong, Wang, Wei-Jan, Wang, Yuan-Liang, Lin, Chen-Yuan, Hung, Mien-Chie, Wang, Shao-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268654/
https://www.ncbi.nlm.nih.gov/pubmed/34203261
http://dx.doi.org/10.3390/ijms22136938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268654/
https://www.ncbi.nlm.nih.gov/pubmed/34203261
http://dx.doi.org/10.3390/ijms22136938

Ejemplares similares